Protagonist Therapeutics (PTGX) Payables (2015 - 2026)

Protagonist Therapeutics has reported Payables for 12 years, with the latest figure at $8.4 million in Q1 2026.

• Quarterly Payables rose 189.24% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 189.24% YoY) and the FY2025 annual result came in at $5.3 million, up 230.59% from the prior year.
• Payables rose to $8.4 million in Q1 2026 per PTGX's latest filing, from $5.3 million in the prior quarter.
• Over five years, Payables peaked at $8.4 million in Q1 2026 and troughed at $772000.0 in Q4 2023.
• A 5-year average of $3.8 million and a median of $3.6 million in 2024 frame the typical range for Payables.
• The widest YoY moves for Payables: up 567.85% in 2022, down 82.14% in 2022.
• Over 5 years, Payables stood at $3.6 million in 2022, then sank by 78.79% to $772000.0 in 2023, then soared by 109.2% to $1.6 million in 2024, then surged by 230.59% to $5.3 million in 2025, then jumped by 58.03% to $8.4 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $8.4 million, $5.3 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.